相关实验视频
Updated: Mar 13, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
1.0K
瘤药物重新利用作为阿尔茨海默氏症治疗方案的蓝图
Viswanath Das1,2, Marián Hajdúch1,2
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc Olomouc Czech Republic.
Alzheimer's & dementia (New York, N. Y.)
|March 12, 2026
概括
重用癌症药物可能为阿尔茨海默病 (AD) 治疗提供一个新的策略. 结合针对多种疾病途径的疗法,可以为患者带来更有效,更持久的益处.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 带来了巨大的负担,目前的治疗方法效果有限.
- 针对阿尔茨海默病的单一目标策略是不够的,因为该疾病的复杂性,多因素性质涉及粉样蛋白,,神经炎症,血管和代谢途径.
研究的目的:
- 探索基于瘤学的药物重定向策略,用于阿尔茨海默病的治疗.
- 倡导使用多目标干预和适应性试验设计的综合治疗开发.
主要方法:
- 利用癌症治疗的原则,包括合理的组合和药物的重新用途.
- 应用基于生物标志物的丰富,系统级药理学和适应性平台试验来开发AD药物.
- 考虑组合疗法的翻译和监管挑战.
主要成果:
- 最近的研究表明,重新使用已批准的抗癌药物可以逆转AD相关的网络功能障碍.
- 瘤药物重定向建立在现有的安全性和药理动力学数据的基础上,可能减少开发时间和成本.
结论:
- 基于瘤学策略的AD综合治疗开发,为更有效的治疗提供了现实的途径.
- 结合多目标干预,生物标志物丰富和适应性试验的跨学科方法可以为阿尔茨海默病带来持久的,人口层面的好处.
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Drug Dosing: Geriatric Patients
339
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
339
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K

